Dihydroartemisinin inhibits histone lactylation through YAP1 to act as a ‘hot’ switch for ‘cold’ tumor in hepatocellular carcinoma
Phytomedicine · 2025-11 · 148 · 157307
DOI: 10.1016/j.phymed.2025.157307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytomedicine, 2025-11. Verfasst von Yuting Gao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, 030000, China. Hauptthemen laut MEDLINE: Artemisinins, Carcinoma, Hepatocellular, Liver Neoplasms, Histones. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Shaanxi University of Chinese Medicine, National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: Hepatocellular carcinoma (HCC) is characterized by a 'cold' tumor microenvironment (TME), which limits the efficacy of immune checkpoint inhibitors (ICIs). In a previous study, we demonstrated that dihydroartemisinin (DHA) could disrupt the immunosuppressive TME and delay HCC progression. PURPOSE: This study aimed to explore the precise mechanisms underlying the shift of the TME from an immunosuppressive to an immunostimulatory state. METHODS: We constructed HCC subcutaneous allograft mice model to investigate the in vivo antitumor effects of DHA. We further performed single-cell RNA sequencing (scRNA-seq) and multiplex immunohistochemistry (mIHC) to analyze the immune dynamics during DHA-induced TME transition in HCC. Using NCG mice (lacking T, B, and NK cells), BALB/c nude mice (lacking T cells), and CD8+ T cell-depleted mice, we assessed whether the antitumor effect of DHA in HCC depends on its immune functions and determined the key role of T cells in antitumor immunity. Additional downstream mechanisms were explored using YAP1 knockdown HCC cells and liver-specific Yap1 knockout mice through techniques such as Western blot, immunofluorescence (IF), metabolic flux analysis, co-immunoprecipitation (Co-IP), chemokine chip, and flow cytometry (FCM). RESULTS: We observed that DHA transforms the TME of HCC from an immune-cold to an immune-hot state by increasing the abundance and proportion of T cells, NK cells, M1-like TAMs, and DCs. Notably, DHA was found to enhance the proportion of IFN-γ+ CD8+ T cells within the TME of HCC-bearing mice, and its therapeutic effects were dependent on CD8+ T cells. Our results suggest that DHA could suppress histone lactylation (Kla) and acetylation (Kac) in HCC cells by inhibiting YAP1. Mechanistically, DHA reduces lactate transport, thereby decreasing lactate accumulation within the TME, lowering P300/CBP catalytic activity, and enhancing the deacetylation effect of HDAC1-3. This finding reveals a new mechanism by which DHA, through metabolic changes and epigenetic regulation, remodels the TME of HCC. Additionally, a combination strategy involving DHA and anti-PD-1 therapy demonstrated the potential to reshape the cold HCC TME via inhibition of the YAP1-lactylation positive feedback loop. CONCLUSION: Our study confirms that DHA inhibits histone Kla in HCC cells through YAP1 inhibition, which shifts the TME from an immune-cold to immune-hot state. Moreover, DHA enhance the anti-HCC immune response dependent on CD8+ T cells, thereby sensitizing anti-PD-1 therapy. This novel finding positions DHA as a promising strategy for optimizing anti-PD-1 therapy in HCC, warranting further clinical application studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, 030000, China.
- Laboratory of Integrated Medicine Tumor Immunology, Shanxi University of Chinese Medicine, Taiyuan, 030000, China. Electronic address: sxlsunshine@sina.com.
Förderung
- Shaanxi University of Chinese Medicine
- National Natural Science Foundation of China
Zitieren
APA
Gao, Y., Gong, Y., Song, X., Xiong, Y., Lu, J., Yang, Y., Gong, Y., Du, Z., Wang, S., Jia, R., Gong, P., & Shi, X. (2025). Dihydroartemisinin inhibits histone lactylation through YAP1 to act as a ‘hot’ switch for ‘cold’ tumor in hepatocellular carcinoma. Phytomedicine, 148, 157307. https://doi.org/10.1016/j.phymed.2025.157307
Vancouver
Gao Y, Gong Y, Song X, Xiong Y, Lu J, Yang Y, et al. Dihydroartemisinin inhibits histone lactylation through YAP1 to act as a ‘hot’ switch for ‘cold’ tumor in hepatocellular carcinoma. Phytomedicine. 2025;148:157307. doi:10.1016/j.phymed.2025.157307
BibTeX
@article{Gao2025,
author = {Gao, Yuting and Gong, Yi and Song, Xiaoyong and Xiong, Yajun and Lu, Junlan and Yang, Yanguang and Gong, Yanli and Du, Zhimin and Wang, Shanshan and Jia, Ruilong and Gong, Peng and Shi, Xinli},
title = {Dihydroartemisinin inhibits histone lactylation through YAP1 to act as a ‘hot’ switch for ‘cold’ tumor in hepatocellular carcinoma},
journal = {Phytomedicine},
year = {2025},
volume = {148},
pages = {157307},
doi = {10.1016/j.phymed.2025.157307}
}
EUVIMED